Mechanistically, SESTD1 appears to modulate immune cell infiltration within the tumor microenvironment and shows a positive correlation with the expression of immune checkpoint molecules PD-1 and PD-L1.<h4>Conclusion</h4>SESTD1 may serve as a diagnostic and prognostic marker, as well as a potential target for immunotherapy in HCC. The gene discussed is SESTD1; the disease is neoplasm.